Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis, PeptiDream ally again; this time in radionuclide PDCs

Executive Summary

In yet another tie-up with a Big Pharma, PeptiDream Inc. has this time partnered with Novartis AG in a new deal to identify macrocyclic/constrained peptides for use as peptide drug conjugates (PDCs) against multiple targets selected by Novartis using PeptiDream's Peptide Discovery Platform System (PDPS), which enables the synthesis, selection, and screening of peptides to identify those exhibiting the greatest cellular penetration and target potency.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
    • Large Molecule
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies